Du forlater nå GSKs nettsider

Denne lenken tar deg til en nettside som ikke tilhører GSK. GSK er ikke ansvarlig for, går ikke god for og aksepterer intet ansvar for informasjon eller meninger på nettsteder til tredjeparter



Practical Tools

Use these tools to find out if your patient with severe refractory asthma could benefit from treatment with Nucala. Nucala is a targeted anti-interleukin (IL)-5 add-on therapy for adults, adolescents and children ≥ 6 years with severe refractory eosinophilic asthma. 1

Could your patients with severe refractory eosinophilic asthma benefit from targeted add-on treatment with Nucala?

Check your patient’s symptoms and use the patient identification chart to make a decision as to whether they are eligible for targeted add-on treatment with Nucala for severe refractory eosinophilic asthma.

The Nucala clinical development programme evaluated efficacy in a targeted group of patients with severe refractory eosinophilic asthma most likely to benefit from treatment, using 3 criteria:

  • Current therapy – high doses of inhaled corticosteroids (ICS, e.g. fluticasone propionate ≥1000 μg or budesonide ≥1600 μg per day2 and an additional maintenance treatment(s)
  • Exacerbation history – two or more exacerbations in the previous 12 months and/or dependency on systemic corticosteroids
  • Blood eosinophil level – ≥150 cells/μL (≥0.15 x 109 cells/L) at initiation of treatment or ≥300 cells/μL (≥0.3 x 109 cells/L) in the prior 12 months (determined through a routine blood test)

Determining your patient’s eosinophil count

The patient’s blood test may already provide the absolute eosinophil count. If the patient’s absolute eosinophil count is not available, it can be calculated by multiplying the percentage of eosinophils by the total white blood cell (WBC) count or by using the calculator below.

Eosinophil calculator

A routine blood test should give you the information you need. Simply enter the total WBC and the percentage of eosinophils in the boxes below to calculate the number of eosinophils in the blood per microliter.

To calculate the absolute eosinophil count

Does your patient have severe asthma and an eosinophil count of ≥150 eosinophil cells/µL (≥0.15 x 109 eosinophil cells/L) or have they had a count of ≥300 eosinophil cells/µL (≥0.3 x 109 eosinophil cells/L) in the past 12 months? If so they may be a candidate for Nucala treatment. 1

Patient Identification


  1. Nucala SmPC.
  2. Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43(2):343-73

Nucala is a trademark of the GSK group of companies